WALTER, Joan, Thomas NESTELBERGER, Jasper BOEDDINGHAUS, Raphael TWERENBOLD, Lukas CROTON, Patrick BADERTSCHER, Karin WILDI, Desiree WUSSLER, Jeanne du Fay DE LAVALLAZ, Christian MUELLER, Maria Rubini GIMENEZ, Christian PUELACHER, Nikola KOZHUHAROV, Beata MORAWIEC, Katharina RENTSCH, Oscar MIRO, F. Javier MARTIN-SANCHEZ, Piotr MUZYK, Nicolas GEIGY, Dagmar I. KELLER, Tobias REICHLIN, Jens LOHRMANN, Ewalina BISKUP, Wanda KLOOS, Beatriz LOPEZ, Carolina Fuenzalida INOSTROZA, Esther Rodriguez ADRADA, Damian KAWECKI, Piotr MUZYK, Ewa NOWALANY-KOZIELSKA, Jiří PAŘENICA, Kathrin MEISSNER, Caroline KULANGARA, Riham MAHFOUZ, Katharina RENTSCH and Arnold VON ECKARDSTEIN. Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarction. International Journal of Cardiology. Clare: Elsevier Ireland Ltd., 2019, vol. 292, October, p. 241-245. ISSN 0167-5273. Available from: https://dx.doi.org/10.1016/j.ijcard.2019.04.088.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarction
Authors WALTER, Joan (756 Switzerland), Thomas NESTELBERGER (756 Switzerland), Jasper BOEDDINGHAUS (756 Switzerland), Raphael TWERENBOLD (756 Switzerland), Lukas CROTON (756 Switzerland), Patrick BADERTSCHER (756 Switzerland), Karin WILDI (756 Switzerland), Desiree WUSSLER (756 Switzerland), Jeanne du Fay DE LAVALLAZ (756 Switzerland), Christian MUELLER (756 Switzerland, guarantor), Maria Rubini GIMENEZ (756 Switzerland), Christian PUELACHER (756 Switzerland), Nikola KOZHUHAROV (756 Switzerland), Beata MORAWIEC (756 Switzerland), Katharina RENTSCH (756 Switzerland), Oscar MIRO (756 Switzerland), F. Javier MARTIN-SANCHEZ (756 Switzerland), Piotr MUZYK (756 Switzerland), Nicolas GEIGY (756 Switzerland), Dagmar I. KELLER (756 Switzerland), Tobias REICHLIN (756 Switzerland), Jens LOHRMANN (756 Switzerland), Ewalina BISKUP (756 Switzerland), Wanda KLOOS (756 Switzerland), Beatriz LOPEZ (724 Spain), Carolina Fuenzalida INOSTROZA (724 Spain), Esther Rodriguez ADRADA (724 Spain), Damian KAWECKI (616 Poland), Piotr MUZYK (616 Poland), Ewa NOWALANY-KOZIELSKA (616 Poland), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Kathrin MEISSNER (756 Switzerland), Caroline KULANGARA (756 Switzerland), Riham MAHFOUZ (756 Switzerland), Katharina RENTSCH (756 Switzerland) and Arnold VON ECKARDSTEIN (756 Switzerland).
Edition International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2019, 0167-5273.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.229
RIV identification code RIV/00216224:14110/19:00110562
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ijcard.2019.04.088
UT WoS 000476878000050
Keywords in English Biomarkers; Acute coronary syndromes; Mortality/survival
Tags 14110211, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/9/2019 10:15.
Abstract
Background: To assess the prognostic performance of Growth differentiation factor-15 (GDF-15) concentrations in unselected patients presenting with suspected acute myocardial infarction (AMI) and adjudication based on high-sensitivity cardiac troponin (hs-cTn). Methods and results: In an ongoing prospective multicenter diagnostic study, consecutive patients presenting with suspected AMI to the emergency department and available GDF-15 and hs-cTnT concentrations were included. Adjudication of AMI was performed central by two independent cardiologists using all available clinical information including cardiac imaging and serial hs-cTn concentrations. Overall, 718 patients were included, with 23% (162/718) having an adjudicated diagnosis of AMI. The cumulative incidence of death within 2 years was 19% in patients with AMI (30 deaths in 162 patients) versus 5% in patients without AMI (25 deaths in 556 patients; P < 0.001). In AMI patients, GDF-15 provided an AUC of 0.89 (95% confidence interval [CI] 0.83-0.94) for 2-year death versus 0.55 (95% CI 0.44-0.66) for hs-cTnT (P < 0.001). A GDF-15 cutoff of <= 1560 ng/L predicted 2-year survival in 47% (76/162) of AMI patients and had 100% sensitivity (95% CI 88-100%) for 2-year death. In patients without AMI, GDF-15 provided an AUC of 0.83 (95% CI 0.76-0.89) versus 0.76 (95% CI 0.67-0.85) for hscTnT (P= 0.096). A GDF-15 cutoff of <= 886 ng/L predicted 2-year survival in 37% (203/556) of non-AMI patients and had 100% sensitivity (95% CI 86-100%) for 2-year death. Conclusions: GDF-15 concentrations at emergency department presentation have a high predictive accuracy for all-cause death in patients with suspected AMI and allow the identification of a large proportion of AMI patients with very low mortality risk. (C) 2019 Elsevier B.V. All rights reserved.
PrintDisplayed: 22/7/2024 14:18